PL4055190T4 - Diagnozowanie zaburzeń nastroju za pomocą biomarkerów edycji rna we krwi - Google Patents

Diagnozowanie zaburzeń nastroju za pomocą biomarkerów edycji rna we krwi

Info

Publication number
PL4055190T4
PL4055190T4 PL20800687.4T PL20800687T PL4055190T4 PL 4055190 T4 PL4055190 T4 PL 4055190T4 PL 20800687 T PL20800687 T PL 20800687T PL 4055190 T4 PL4055190 T4 PL 4055190T4
Authority
PL
Poland
Prior art keywords
biomarkers
diagnosis
blood
mood disorders
rna editing
Prior art date
Application number
PL20800687.4T
Other languages
English (en)
Other versions
PL4055190T3 (pl
Inventor
Dinah Weissmann
Nicolas Salvetat
Fabrice Chimienti
Original Assignee
Alcediag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcediag filed Critical Alcediag
Publication of PL4055190T3 publication Critical patent/PL4055190T3/pl
Publication of PL4055190T4 publication Critical patent/PL4055190T4/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00—Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10—Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/165—Mathematical modelling, e.g. logarithm, ratio
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Data Mining & Analysis (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Wood Science & Technology (AREA)
  • Evolutionary Biology (AREA)
  • Zoology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Software Systems (AREA)
  • Public Health (AREA)
  • Evolutionary Computation (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PL20800687.4T 2019-11-08 2020-11-09 Diagnozowanie zaburzeń nastroju za pomocą biomarkerów edycji rna we krwi PL4055190T4 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19208124.8A EP3819386A1 (en) 2019-11-08 2019-11-08 Diagnosing of mood disorders using blood rna editing biomarkers
PCT/EP2020/081458 WO2021089865A1 (en) 2019-11-08 2020-11-09 Diagnosing of mood disorders using blood rna editing biomarkers

Publications (2)

Publication Number Publication Date
PL4055190T3 PL4055190T3 (pl) 2024-12-16
PL4055190T4 true PL4055190T4 (pl) 2024-12-16

Family

ID=68501510

Family Applications (1)

Application Number Title Priority Date Filing Date
PL20800687.4T PL4055190T4 (pl) 2019-11-08 2020-11-09 Diagnozowanie zaburzeń nastroju za pomocą biomarkerów edycji rna we krwi

Country Status (11)

Country Link
US (1) US20250270641A1 (pl)
EP (2) EP3819386A1 (pl)
JP (1) JP7859969B2 (pl)
KR (1) KR20220097469A (pl)
CN (1) CN114929898A (pl)
BR (1) BR112022008886A2 (pl)
CA (1) CA3155714A1 (pl)
ES (1) ES2993857T3 (pl)
IL (1) IL292587A (pl)
PL (1) PL4055190T4 (pl)
WO (1) WO2021089865A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3819387A1 (en) * 2019-11-08 2021-05-12 Alcediag Differential diagnosis of bipolar disorder and unipolar depression by blood rna editing biomarkers
CN114334090B (zh) * 2022-03-02 2022-07-12 博奥生物集团有限公司 一种数据分析方法、装置及电子设备
EP4389915A1 (en) 2022-12-21 2024-06-26 Alcediag Differential diagnosing of bipolar versus unipolar disorder in patient during depression phases using a to i rna editing znf267 gene
WO2025012793A1 (en) * 2023-07-08 2025-01-16 University Of Sharjah A method for determining biomarker(s) pertaining to mental health disorder(s) and biomarker(s) determined therefrom
WO2025233372A1 (en) * 2024-05-06 2025-11-13 Alcediag Method for differentiating patients across healthy control, bipolar disorder, schizophrenia, and schizoaffective groups

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2952748T3 (es) * 2007-06-13 2023-11-03 Alcediag Muestra de tejido periférico que contiene células que expresan el 5HTR2C y/o las ADAR como marcadores de la alteración del mecanismo de edición del ARNm de 5HTR2C y sus aplicaciones
CA3016657A1 (en) * 2016-03-11 2017-09-14 Alcediag Algorithm and an in vitro method based on rna editing to select particular effect induced by active compounds
US11104953B2 (en) * 2016-05-13 2021-08-31 Children's Hospital Medical Center Septic shock endotyping strategy and mortality risk for clinical application
WO2018020042A1 (en) * 2016-07-28 2018-02-01 Alcediag Rna editing as biomarkers for mood disorders test
EP3819387A1 (en) * 2019-11-08 2021-05-12 Alcediag Differential diagnosis of bipolar disorder and unipolar depression by blood rna editing biomarkers

Also Published As

Publication number Publication date
PL4055190T3 (pl) 2024-12-16
JP7859969B2 (ja) 2026-05-15
EP4055190A1 (en) 2022-09-14
CN114929898A (zh) 2022-08-19
WO2021089865A1 (en) 2021-05-14
BR112022008886A2 (pt) 2022-08-23
ES2993857T3 (en) 2025-01-10
EP4055190C0 (en) 2024-07-03
EP4055190B1 (en) 2024-07-03
EP3819386A1 (en) 2021-05-12
US20250270641A1 (en) 2025-08-28
JP2023500845A (ja) 2023-01-11
KR20220097469A (ko) 2022-07-07
CA3155714A1 (en) 2021-05-14
IL292587A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
PL4055190T3 (pl) Diagnozowanie zaburzeń nastroju za pomocą biomarkerów edycji rna we krwi
PL4055191T3 (pl) Diagnostyka różnicowa choroby afektywnej dwubiegunowej i nawracających zaburzeń depresyjnych za pomocą biomarkerów edycji rna we krwi
EP3411720C0 (en) METHODS OF DIAGNOSIS AND PROGNOSIS OF CARDIOVASCULAR DISEASES AND EVENTS
EP3359171C0 (en) Use of akkermansia muciniphila for treating inflammatory conditions
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
HUE047951T2 (hu) Vér alapú biomarkerek atheroszklerotikus koszorúsér betegség diagnosztizálására
DOP2012000104A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
EP3383411C0 (en) SUB-MITOCHONDRIAL PARTICLES FOR USE IN THE TREATMENT OF METABOLIC DISEASES
IL281504A (en) Methods and kits for preparing pathogen-inactivated whole blood
EP3586129C0 (en) Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
EP3490677A4 (en) LIPID, PROTEIN AND METABOLITE MARKER FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER
EP3661527A4 (en) MULTI-BIOMARKER DISEASE ACTIVITY SCORE ADJUSTED TO ASSESS INFLAMMATORY DISEASE
EP3592850B1 (en) PREPARATION AND USE OF GLU-PLASMINOGENE FROM BLOOD FRACTIONS
EP3356832A4 (en) BIOMARKERS AND METHOD FOR ASSESSING THE DISEASE ACTIVITY OF PSORIASIS TARTHRITIS
HRP20260406T1 (hr) Lumateperon za primjenu u liječenju shizofrenije
EP3458836C0 (en) NON-INVASIVE BLOOD ANALYSIS
EP3902556A4 (en) IN VIVO MANIPULATED CEREBLON PROTEIN
EP3765476C0 (en) MODIFIED OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF TAUOPATHIES
EP3836157C0 (en) METHOD FOR OBTAINING CLINICAL INFORMATION RELATED TO A DISEASE
EP3887514A4 (en) THERAPEUTIC GENERATE EDITING FOR ELAN-ASSOCIATED DISEASE
ME02993B (me) Laktoferin za upotrebu u dijagnozi ili prognozi alchajmerove bolesтi
EP3655433A4 (en) PROCEDURES AND USES OF BIOMARKERS FOR INFLAMMATORY INTESTINAL DISEASE
SI3826997T1 (sl) Postopek in intermediati za pripravo bilastina
EP3445448A4 (en) THERAPEUTIC AGENTS FOR SKIN CONDITIONS AND METHODS OF USE
EP3820487A4 (en) Gene editing for autoimmune disorders